 |
|
|
 |
|
|
|
|
|
|
| Creative Lynx is rapidly developing a blooming reputation within the healthcare sector as a creative agency that provides exceptional service and gets quantifiable results. |
|
In 2005 we were one of only six teams to make it through to the Pharma Times Ad Agency of the Year finals and we also won a
much coveted PMEA Brand Revitalisation award for our work on
Zoton FasTab. |
|
| Our dedicated pharmaceutical team believe in spending time getting to know you and your business. That way we can work together to develop outstanding campaigns and effective communications, at both a local and a global level. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We would be delighted to discuss any projects that do not present
a conflict of interests. Our dedicated pharmaceutical capability and wealth of experience enables us to generate fresh ideas for
products at any stage in their life cycle - from pre-launch through to
re-branding. Most importantly we are looking for like-minded people who work hard, play hard and know the meaning of good branding and a good time. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AstraZeneca is one of the world's leading pharmaceutical companies, with products available in over 100 countries. |
|
| Creative Lynx has recently produced a new international campaign for Arimidex, a drug used for the treatment of breast cancer in postmenopausal women. |
|
| Their product portfolio includes many world leading drugs and a range of high potential therapies for the treatment of cancer (Casodex, Arimidex and Faslodex), gastrointestinal disease (Nexium),
asthma (Symbicort). Hypertension (Atacand), high cholesterol (Crestor), migraine (Zomig) and schizophrenia (Seroquel). |
|
| They also have a promising early development pipeline with 17 projects in phase 1, 17 projects in phase 2 and 25 projects in phase 3 development. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fresenius Kabi is Europe's leading provider of clinical nutrition and infusion therapy. They offer a unique and
comprehensive range of products and services for the care and treatment of chronically and critically ill patients, both in a hospital or home setting. |
|
| Creative Lynx is involved in the development of corporate materials for Fresenius Kabi and promotional materials for their volume therapy, parenteral and enteral nutrition products and services. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Creative Lynx were appointed to work on both the Novartis ophthalmology and transplantation portfolios in 2005. |
|
| Currently, their transplantation portfolio includes Myfortic, Simulect and Neoral, which is its biggest selling transplantation product and was its fifth biggest selling product overall in 2004, with worldwide sales of approximately $1 billion. |
|
| Novartis' transplantation pipeline includes promising molecules in development including a new drug for the prevention of organ rejection: Certican, which has been filed with US regulators |
|
| In ophthalmology the company hopes to file its new age-related macular degeneration (AMD) treatment Lucentis with European regulators in 2006. In the medium to longer term, Novartis will also file for a new indication for Sandostatin LAR, in diabetic eye disease, and a new topical indication for the immunosuppressant treatment Elidel. Novartis' current ophthalmics portfolio includes Visudyne, Viscotears, Voltarol Ophtha and Vitalux Plus. |
|
| Creative Lynx is currently involved in the rewriting and redesigning of many of their existing transplantation and ophthalmology materials, as well as the strategic and creative development of campaigns for the launch of their new, pipeline drugs. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oxford Immunotec is a rapidly growing international diagnostics company with headquarters near Oxford. They develop novel products, based on their patented T-SPOT technology, which have addressed major unmet scientific and medical needs for the diagnosis and monitoring of infection and disease. |
|
| Creative Lynx produce all of the promotional materials for T-SPOT. TB, the company's leading product, which is a major advance in the fight against the global resurgence of tuberculosis. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Serono is the third largest biotech company in the world,
with products sold in over 90 countries. The Company has
eight biotechnology products, Rebif®, Gonal-F®, Luveris®, Ovidrel®/Ovitrelle®, Serostim®, Saizen®, Zorbtive® and Rapitva®. In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, they have approximately 30 ongoing development projects.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sinclair Pharma is an international speciality pharmaceutical company which focuses on the sourcing and acquisition of innovative new products. The company is currently experiencing strong sales growth, particularly in the areas of dermatology (Atopiclair) and oral health (Aloclair and Decapinol). Their portfolio includes 13 products registered in the EU, 9 registered in the US and more than 10 currently in the development pipeline. |
|
| Creative Lynx have been involved in the design and development of corporate materials for Sinclair Pharma. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Takeda is a research-based global pharmaceutical company which focuses mainly on 3 key therapeutic areas: diabetes (Actos), hypertension and heart failure (Amias). They have 2 research centres in Japan, development operations in Japan, the US and Europe and their products are available in over 100 countries worldwide. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trinity-Chiesi is the UK division of Chiesi, a leading European pharmaceutical company which has affiliates throughout the world. They currently deliver a range of medicines focusing on 3 key therapeutic areas: respiratory, cardiovascular and neonatology. They are set to experience huge growth over the next 5 years particularly in the respiratory area, due to the development of their unique Modulite® technology, which enables the conversion to CFC free inhalers. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Wyeth are one of the fastest growing healthcare companies in the UK who have built an impressive new product pipeline across a wide range of therapeutic areas. |
|
| Creative Lynx works on both Tazocin, a hospital antibiotic, and has recently won a PMEA Brand Revitalisation Award for its work on Zoton FasTab, an oro-dispersible proton pump inhibitor.
|
|
|
|
|
|
|
|
|
|
